ArticleWorld journal of microbiology & biotechnology2026
Flower-shaped ZnO nanoparticles from Lactococcus lactis LAB2: potential selective anti-cancer activity via oxidative stress modulation.
Article in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biosynthesized zinc oxide nanoparticles (ZnO-NP2) produced using Lactococcus lactis culture supernatant demonstrate exceptional selectivity as anticancer agents. These flower-like nanoparticles maintained 96.44% viability in normal HUVEC cells, while reducing the viability of HCT116 and K562 cancer cells to 58.92% and 39.24%, respectively, at a concentration of 0.25 mg/mL. Acridine orange-ethidium bromide staining confirmed dose-dependent apoptosis induction, with K562 cells exhibiting a combined apoptotic and necrotic population of 61.66%. Oxidative stress analysis revealed sophisticated cell-type-specific redox modulation, including a 46.9% upregulation of catalase compared to the control in HCT116 cells, elevated lipid peroxidation, and increased levels of nitric oxide and glutathione. Gene expression analysis revealed dramatic alterations in the apoptotic pathway: HCT116 cells exhibited a 29.68-fold upregulation of BAX, while K562 cells demonstrated a 0.05-fold downregulation of BCL2. Physicochemical characterization confirmed successful synthesis with protein coating (evidenced by FTIR peak at 1635.95 cm⁻¹), negative surface charge (-25 to -30 mV), and crystalline flower-like morphology. Paradoxically, ZnO-NP2 showed antioxidant activity in cell-free DPPH assays (63.15% reduction) despite pro-oxidant effects in cancer cells. ZnO-NP2 induced selective cancer cell apoptosis through modulation of oxidative stress and activation of the intrinsic apoptotic pathway in vitro, suggesting preliminary potential for development as targeted anticancer agents, pending comprehensive in vivo validation and mechanistic studies.
Indexed as
Identifiers
41528372What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.